Pieter W A Meyer1,2, Mahmood T M Ally3,4, Bridget Hodkinson5,6, Ronald Anderson7, Mohammed Tikly5,6. 1. Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pathology Building, 5 Bophelo Rd, Prinshof Campus, Pretoria, South Africa. pieter.meyer@up.ac.za. 2. Tshwane Academic Division of the National Health Laboratory Service, Pretoria, South Africa. pieter.meyer@up.ac.za. 3. Department Internal Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa. 4. Steve Biko Academic Hospital, Pretoria, South Africa. 5. Division of Rheumatology, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. 6. Chris Hani-Baragwanath Academic Hospital, Soweto, South Africa. 7. Department of Immunology, Faculty of Health Sciences, University of Pretoria, Pathology Building, 5 Bophelo Rd, Prinshof Campus, Pretoria, South Africa.
Abstract
PURPOSE: A retrospective comparison of the prevalence and diagnostic value of anti-Sa, anti-CEP-1, and anti-MCV autoantibodies relative to those of the established autoantibodies, composite RF and anti-CCP-IgG used routinely for RA diagnosis as a component of the ACR 2010 criteria, in a cohort of disease-modifying anti-rheumatic drug naïve African RA patients (n = 75). METHODS: Serum concentrations of anti-Sa, anti-CEP-1 and anti-MCV autoantibodies were measured using ELISA procedures, while anti-CCP-IgG antibodies were determined by fluorescence enzyme immunoassay, and composite RF by latex-enhanced laser nephelometry. RESULTS: The seropositivity frequencies of anti-Sa, anti-CEP-1 and anti-MCV antibodies for the RA patients were 82, 72, 85%, respectively, while that of anti-CCP-IgG and RF was 87% for both. Overall, anti-MCV demonstrated the best specificity, positive predictive value (PPV), odds ratio and positive likelihood ratio of all the types of autoantibody tested. CONCLUSION: These observations in this unique cohort of RA patients indicated novel associations of all three autoantibodies in regard to HLA-SE risk alleles, disease severity and tobacco use that were not reported before. Elevated anti-Sa titers designated a propensity of higher disease and high-risk alleles in our cohort. Anti-CEP-1 association with HLA-SE homozygosity and high-risk alleles is also novel in this group. Of note, measurement of anti-MCV antibodies on presentation, either as an adjunctive or even as a stand-alone test, surpassed all other biomarkers investigated here and, therefore, may add value to clinical management.
PURPOSE: A retrospective comparison of the prevalence and diagnostic value of anti-Sa, anti-CEP-1, and anti-MCV autoantibodies relative to those of the established autoantibodies, composite RF and anti-CCP-IgG used routinely for RA diagnosis as a component of the ACR 2010 criteria, in a cohort of disease-modifying anti-rheumatic drug naïve African RApatients (n = 75). METHODS: Serum concentrations of anti-Sa, anti-CEP-1 and anti-MCV autoantibodies were measured using ELISA procedures, while anti-CCP-IgG antibodies were determined by fluorescence enzyme immunoassay, and composite RF by latex-enhanced laser nephelometry. RESULTS: The seropositivity frequencies of anti-Sa, anti-CEP-1 and anti-MCV antibodies for the RApatients were 82, 72, 85%, respectively, while that of anti-CCP-IgG and RF was 87% for both. Overall, anti-MCV demonstrated the best specificity, positive predictive value (PPV), odds ratio and positive likelihood ratio of all the types of autoantibody tested. CONCLUSION: These observations in this unique cohort of RApatients indicated novel associations of all three autoantibodies in regard to HLA-SE risk alleles, disease severity and tobacco use that were not reported before. Elevated anti-Sa titers designated a propensity of higher disease and high-risk alleles in our cohort. Anti-CEP-1 association with HLA-SE homozygosity and high-risk alleles is also novel in this group. Of note, measurement of anti-MCV antibodies on presentation, either as an adjunctive or even as a stand-alone test, surpassed all other biomarkers investigated here and, therefore, may add value to clinical management.
Authors: Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker Journal: Arthritis Rheum Date: 2010-09
Authors: Sophie Tezenas du Montcel; Laetitia Michou; Elisabeth Petit-Teixeira; José Osorio; Isabelle Lemaire; Sandra Lasbleiz; Céline Pierlot; Patrick Quillet; Thomas Bardin; Bernard Prum; François Cornelis; Françoise Clerget-Darpoux Journal: Arthritis Rheum Date: 2005-04
Authors: Benjamin A Fisher; Darren Plant; Monica Brode; Ronald F van Vollenhoven; Linda Mathsson; Deborah Symmons; Karin Lundberg; Johan Rönnelid; Patrick J Venables Journal: Ann Rheum Dis Date: 2011-03-01 Impact factor: 19.103
Authors: Natalia Wegner; Karin Lundberg; Andrew Kinloch; Benjamin Fisher; Vivianne Malmström; Marc Feldmann; Patrick J Venables Journal: Immunol Rev Date: 2010-01 Impact factor: 12.988
Authors: Holger Bang; Karl Egerer; Anke Gauliard; Kirsten Lüthke; Paul E Rudolph; Gert Fredenhagen; Wigbert Berg; Eugen Feist; Gerd-R Burmester Journal: Arthritis Rheum Date: 2007-08
Authors: Pieter W A Meyer; Bridget Hodkinson; Mahmood Ally; Eustasius Musenge; Ahmed A Wadee; Heidi Fickl; Mohammed Tikly; Ronald Anderson Journal: Mediators Inflamm Date: 2011-03-02 Impact factor: 4.711
Authors: Miriam Lizette Díaz-Toscano; Eva Maria Olivas-Flores; Soraya Amali Zavaleta-Muñiz; Jorge Ivan Gamez-Nava; Ernesto German Cardona-Muñoz; Manuel Ponce-Guarneros; Uriel Castro-Contreras; Arnulfo Nava; Mario Salazar-Paramo; Alfredo Celis; Nicte Selene Fajardo-Robledo; Esther Guadalupe Corona-Sanchez; Laura Gonzalez-Lopez Journal: Biomed Res Int Date: 2014-06-15 Impact factor: 3.411
Authors: Erik R Vossenaar; Normand Després; Elvy Lapointe; Annemarie van der Heijden; Maximillian Lora; Tatsuo Senshu; Walther J van Venrooij; Henri A Ménard Journal: Arthritis Res Ther Date: 2004-02-05 Impact factor: 5.156
Authors: Pieter W A Meyer; Mahmood M T M Ally; Mohammed Tikly; Gregory Tintinger; Lai Ling Winchow; Helen Steel; Ronald Anderson Journal: Mediators Inflamm Date: 2019-11-03 Impact factor: 4.711